New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:48 EDTLGND, ONXXLigand Pharma should benefit significantly from Onyx drug, says Roth Capital
After Onyx (ONXX) reported $18.6M in Kyprolis sales for Q3, Roth Capital notes that Ligand (LGND) receives a 3% average royalty on Kyprolis sales. The firm believes that Kyprolis will help enable Ligand to rapidly become profitable and it maintains a $25 target and Buy rating on the stock.
News For LGND;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:28 EDTLGNDLigand sees 2015 revenue $81M-$83M, consensus $91.87M
Three estimates make up consensus. Guidance issued in analyst day presentation slides.
10:27 EDTLGNDLigand sees 2017 EPS above $4.65, revenue above $146M
Subscribe for More Information
10:27 EDTLGNDLigand sees 2016 EPS above $3.20, revenue above $107M
Subscribe for More Information
10:25 EDTLGNDLigand guides 2015 EPS $2.14-$2.18, consensus $2.42
Subscribe for More Information
November 17, 2014
07:16 EDTONXXMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link
November 12, 2014
09:16 EDTLGNDLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use